UMN Pharma to Manufacture, Sell Protein Sciences' Flu Vaccine in Japan

Aug 29, 2006

NEW YORK (GenomeWeb News) – Protein Sciences has licensed its FluBiok recombinant influenza vaccine to Japanese biotech UMN Pharma to make and sell the product in that market.

Terms of the deal call for PSC to transfer technology to UMN, which will register, manufacture, market, and sell the vaccine in Japan for annual and pandemic use.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Halt Under Consideration

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

How's It Going to Go Over?

The Associated Press reports that gene-edited food may soon be for sale.

Meetings on Fetal Research

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

This Week in Cell

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.

Main menu